Study of Immune Cell Treatment Using Patients Own Blood Cells Before Embryo Transfer to Improve IVF Success

What this Trial Is About

This research aims to assess the effect of specialized immune cells taken from a patients own blood and treated with interferon tau IFNt when placed in the uterus before embryo transfer, on the success of in vitro fertilization IVF. The trial focuses on improving implantation, pregnancy, and live birth rates in women undergoing IVF, comparing outcomes with a control group that does not receive this cell treatment. The study is randomized and double-blinded to ensure unbiased results. Eligible female patients with no uterine problems and scheduled for embryo transfer will have their peripheral blood mononuclear cells PBMC isolated five days after the luteinizing hormone LH surge. These cells are treated with IFNt for 24 hours and then introduced into the uterine cavity on day 6 after the LH peak. Embryo transfer is conducted the following day. A control group will undergo the standard embryo transfer without receiving the treated cells. Participants will have blood collected and undergo embryo transfer according to schedule. Researchers will monitor implantation rates at 4 to 6 weeks post-transfer, clinical pregnancy rates at 6 weeks, and live birth rates up to 10 months after embryo transfer. Data analysis will be done without knowledge of group assignment. The total participation duration includes treatment and follow-up assessments to evaluate reproductive outcomes.

Effect of Intrauterine Administration of Autologous PBMC Modulated With IFNt on IVF Outcome